Start reading ,This title and over 12000 thousand more,available with Avenue Library, T&C*
Pulmonary Hypertension Drug Market by Product (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors and Soluble Guanylate Cyclase Stimulators), and by Application (Early-Stage Drug Candidates (Phase I & Phase II) and Late-Stage Drug Candidates (Phase III & Registration Phase)) - Global Opportunity Analysis and Industry Forecast, 2021-2028
| A03661 | Pages: NA | Aug 2021 | 3618 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Pulmonary Hypertension Drug Market
Request Now !Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.
Factors such as increase in geriatric population, healthcare expenditure, prevalence of hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects associated with the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.
The market is segmented on the basis of product, application, and region. By product, the market is divided into prostacyclin & prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. Based on application, the market is categorized into early-stage drug candidates (phase I & phase II) and late-stage drug candidates (phase III & registration phase). By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
- The study provides an in-depth analysis of the pulmonary hypertension drug market, with current trends and future estimations to elucidate investment pockets.
- Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
- The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities from 20172023 in terms of value.
- Extensive analysis of different segments helps understand various products of the market.
- Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
Pulmonary Hypertension Drug Market Key Segments:
By Product
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists
- Phosphodiesterase-5 Inhibitors
- Soluble Guanylate Cyclase Stimulators
By Application
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- The Middle East
- Africa
List of players profiled in the report
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co., Inc.
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd.
- Vectura Group plc
- Pfizer Inc.
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 PULMONARY HYPERTENSION MARKET , BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PROSTACYCLIN AND PROSTACYCLIN ANALOGS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. ENDOTHELIN RECEPTOR ANTAGONISTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. PHOSPHODIESTERASE-5 INHIBITORS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. SOLUBLE GUANYLAYE CYCLASE STIMULATORS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 PULMONARY HYPERTENSION MARKET , BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. EARLY STAGE DRUG CANDIDATES (PHASE I & II)
5.2.1. Market size and forecast
5.3. LATE STAGE DRUG CANDIDATES (PHASE III & REGISTRAION PHASE)
5.3.1. Market size and forecast
5.3.2. Market size and forecast
CHAPTER 6 PULMONARY HYPERTENSION MARKET , BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Pulmonary Hypertension Market by Product
6.2.5. North America Pulmonary Hypertension Market by Application
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. UK market size and forecast
6.3.3.2. Germany market size and forecast
6.3.3.3. France market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Italy market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Pulmonary Hypertension Market by Product
6.3.5. Europe Pulmonary Hypertension Market by Application
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. China market size and forecast
6.4.3.2. Japan market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Pulmonary Hypertension Market by Product
6.4.5. Asia-Pacific Pulmonary Hypertension Market by Application
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Latin America market size and forecast
6.5.3.2. The Middle East market size and forecast
6.5.3.3. Africa market size and forecast
6.5.4. LAMEA Pulmonary Hypertension Market by Product
6.5.5. LAMEA Pulmonary Hypertension Market by Application
CHAPTER 7 COMPANY PROFILES
7.1. GLAXOSMITHKLINE PLC
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. NOVARTIS AG
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. MERCK & CO., INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. ABBOTT LABORATORIES
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. BOEHRINGER INGELHEIM GMBH
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. ASTRAZENECA PLC
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. F. HOFFMANN-LA ROCHE AG
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. VECTURA GROUP PLC
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. PIFIZER INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
REQUEST TOC/SAMPLE
Purchase Full Report of
Pulmonary Hypertension Drug Market- Global Opportunity Analysis and Industry Forecast, 2021-2028
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers